GasthuisZusters Antwerpen — Clinical Trial Site

42 Registered trials

8 Currently recruiting

Organisation

GasthuisZusters Antwerpen

Location

Antwerp, Belgium

Identifier

ORG-100028893

Address

Sint-Vincentiusstraat 20, 2018, Belgium

Departments

3001:Oncologie
Cardiology
Center for Reproductive Medicine
Clinical Research Oncology
Department of Oncology
Gastro enterology
Gastro-enterology
Gastroenterology
Gynaecologie-verlsokunde
Hematology
Medical Oncology
Medische Oncologie
N/A
Oncologie
Oncologisch Centrum
Oncology
Oncology (CTO)
Oncology Center
Oncology Centre
Radiotherapie
Radiotherapie-oncologie
radiotherapy

Clinical trials at this site (42)

Search interface

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502798-40-00 Patients with resected colon carcinoma 5 2017-07-31
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi… Ended

2023-509348-84-00 Chronic Lymphocytic Leukemia 5 2015-04-27
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C… Ended

2024-514532-24-00 Solid cancer tumors 3 2022-06-23
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Participants with completely resected Stage III or Stag 5 2021-12-03
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Advanced solid tumors 9 2021-07-28
An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Ad… Ended

2023-506285-31-00 Locally Advanced or Metastatic Solid Tumors 1 2021-04-21
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) Ended

2024-511140-37-00 OligoRecurrent prostate cancer 4 2021-02-12
Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended

2022-501972-25-00 Locally Advanced Cervical Cancer 5 2020-04-06
A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in… Ended

2024-512158-12-00 Bladder Cancer Muscle-Invasive Bladder Cancer 5 2018-12-14
A Study to Evaluate Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally… Ended

2023-504224-26-00 Advanced tumors 1 2018-07-03
A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended

2023-507271-21-00 Follicular Lymphoma 5 2017-04-11